The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

WASHINGTON -- Children who are healthy but abnormally short will be able to have injections of growth hormone in hopes of gaining 1 to 3 more inches of height, the Food and Drug Administration said ...

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Growth hormone treatment is a safe and effective therapy that’s often used to treat children and adults with a deficiency in human growth hormone (also known as HGH or somatropin). Naturally-occurring ...

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...

Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...

NEW YORK (Reuters Health) - Daily injections of growth hormone may help reduce pain and improve the quality of life in some patients with fibromyalgia, new findings of a small study suggest.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...